$HCTI

Healthcare Triangle Received Notice of Delisting

Nasdaq notified Healthcare Triangle (HCTI) of a delisting due to noncompliance with the $1.00 minimum bid price rule and prior reverse splits. The company plans to appeal, which would stay the suspension and allow continued trading under HCTI.

Original reporting
Published Oct 2, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Healthcare Triangle Received Notice of Delisting — source image
Decision brief

The 30-second read

$HCTIBearishMed
01

Why it matters

The notice creates immediate downside risk; investors may liquidate positions ahead of a possible trading suspension on Oct 12.

02

Market read

The delisting notice is a material corporate action for HCTI, likely prompting price declines and influencing micro‑cap market sentiment.

03

What to watch

Potential for a reverse split or capital raise that could restore compliance.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Healthcare Triangle, Inc. (HCTI) received a Nasdaq delisting notice for failing to meet the $1.00 minimum bid price rule and for multiple reverse splits.

Company-level read

Ticker impact

$HCTIBearishHigh confidence
Context

Nasdaq issued a Staff Delisting Determination for Healthcare Triangle due to $1.00 bid price non‑compliance and prior reverse splits.

Expected impact

likely downward pressure as investors anticipate suspension and possible loss of listing.

Evidence & confidence

Delisting notices historically trigger sell‑offs; the company must appeal by Oct 8 or face trading halt on Oct 12.

Market effects

May raise scrutiny on other low‑price Nasdaq stocks.

Limited to U.S. micro‑cap segment.

Minimal.

Counterpoint

If the company successfully appeals, the delisting risk could be mitigated, offering a short‑term buying opportunity.

Key entities

  • Nasdaq

    Issuer of the delisting determination.

  • Healthcare Triangle, Inc.

    Subject of the delisting notice.

Related articles

$HCTIMedAI 8/10

Healthcare Triangle Reports 322% Increase in Gross Profit and 158% Increase in Revenue for Q2 2026

Healthcare Triangle (Nasdaq: HCTI) reported Q2 2026 revenue of $9.19 million, up 158% year over year, and gross profit of $2.07 million, up 322%. The AI platform contributed about 69% of revenue and gross margin rose to 22.5% from 13.8%. The Teyame and Datono acquisition added $6.31 million revenue. Stockholders’ equity rose to $49.1 million from $9.9 million.

$HCTIMed

Healthcare Triangle, Inc.: Healthcare Triangle Reports 322% Increase in Gross Profit and 158% Increase in Revenue for Q2 2026

Healthcare Triangle, Inc. (Nasdaq: HCTI) reported Q2 2026 revenue of $9.19M, up 158% year over year, and gross profit of $2.07M, up 322%. The AI platform contributed about 69% of revenue and gross margin rose to 22.5% from 13.8%. The Teyame and Datono acquisition contributed $6.31M revenue. Stockholders’ equity rose to $49.1M from $9.9M.

$HCTIMedAI 8/10

Healthcare Triangle Signs Non-Binding LOI to Acquire 51% of CosmoInnovations; Enters High-Growth Proprietary MedTech and Consumer-Health Markets

Healthcare Triangle (Nasdaq: HCTI) said it signed a non-binding LOI to acquire a 51% stake in CosmoInnovations (CosmoAesthetics Pty Ltd). Proposed consideration is $23.5 million over three years via cash, equity, and performance milestones. The deal would add 27 granted international patents and 61 pending applications, targeting over $50 million cumulative revenue in three years.

$RIOMed

Rio Tinto To Invest $1.9 Bln In Queensland Bauxite Project

Rio Tinto (RIO.AX) plans to invest $1.9 billion in the Kangwinan bauxite project in Queensland, Australia, adding 20 million tonnes of annual production capacity by 2032. The project aims to replace output from aging mines and increase Weipa Operations' capacity to 44 million tonnes. Construction is set to begin in 2027, creating 1,300 jobs. The investment follows Rio Tinto's recent acquisition of the adjacent Aurukun Bauxite Project.